Additionally, it was observed that in the context of B2M defect, antigen recognition by CTLs is impaired, while other immune cells (such as CD4+ T lymphocytes, NK cells, and γδ T cells) may still retain their ability to kill tumor, further indicating that the activation of these cells can overcome immunotherapy resistance caused by B2M deficiency. The gene discussed is CD4; the disease is neoplasm.